glp-1 agonists reduce inflammation Frontiers Targeting GLP-1, GIP & GCG

In 2014, the FDA approved the first of these drugs specifically for weight loss for people with a BMI of 30 and above or a BMI of at least 27 with one weight-related comorbid disease, which affects more than half the U.S

Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes

In FLOW, semaglutide improved kidney outcomes in patients with type 2 diabetes and chronic kidney disease. What GLP-1 and GLP-1/GIP Medications Do Not Do 1) They Do NOT Treat Autoimmune Disorders Autoimmune diseases involve immune-system pathways such as T-cell activation, autoantibody production, complement activation, and immune cytokine dysregulation

GLP-1 agonists mimic the GLP-1 hormone, helping regulate insulin, glucose, and appetite

GLP-1s are approved for weight loss in adults who have a body mass index of 30 or higher, and those who are overweight with a body mass index of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol and type 2 diabetes

A consensus document put out by the American College of Sports Medicine suggests 75 minutes per week of vigorous intensity physical activity as an alternative exercise regimen